The anti-CD22 Antibody-Drug Conjugates comprise a drug moiety, an anti-CD22 antibody and a hydrophilic self-immolative linker. The antibody in this ADC compound specifically target human cluster of differentiation-22, which belongs to the SIGLEC family of lections. Therefore the anti-CD22 ADC compound can be used in the treatment or diagnosis of hematological malignancy.
Figure 1 Evaluation of growth-inhibition and apoptosis in D1–1 and Ramos cells.
Cell viabilitydetermined by the MTS assay after 4-day incubation for the Dried-I format of epratuzumab(hLL2*) or labetuzumab (hMN-14*).
Chang, C. H., Wang, Y., Gupta, P., & Goldenberg, D. M. (2015, January). Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. In MAbs (Vol. 7, No. 1, pp. 199-211). Taylor & Francis.
Figure 2 Cytotoxicity of epratuzumab in various formats to Daudi cells.
Epratuzumab pre-sented as the Dried-I (hLL2*) or Wet-III (hLL2 C GAH C anti-IgM) format (right panel), but not theWet-I (hLL2) or Wet-IIB (hLL2 C GAH) format (left panel), induced dose-dependent cytotoxicity inDaudi cells, as measured by the MTS assay.
Chang, C. H., Wang, Y., Gupta, P., & Goldenberg, D. M. (2015, January). Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. In MAbs (Vol. 7, No. 1, pp. 199-211). Taylor & Francis.
Figure 3 Cytotoxicity of epratuzumab in various formats to Daudi cells.
The Dried-I format of epratuzumab (hLL2*)induced apoptosis comparable to the positive control (anti-IgM) as determined by the Annexin Vassay.
Chang, C. H., Wang, Y., Gupta, P., & Goldenberg, D. M. (2015, January). Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. In MAbs (Vol. 7, No. 1, pp. 199-211). Taylor & Francis.
Figure 4 Phosphorylation of CD79a, CD79b, and CD22.
Western blot analyses of phosphorylated CD79a, CD79b,and CD22 in D1–1 cells treated for 2 h with various formats of soluble epratuzumab, including Wet-I(lane 4; hLL2, 7.5 mg/mL), Wet-IIA (lane 5; hLL2, 7.5 mg/mL; GAH, 10 mg/mL), and Wet-III (lane 7; hLL2, 7.5 mg/mL;GAH, 10 mg/mL; anti-IgM, 1 mg/mL). In lane 6, the amounts of GAH and anti-IgM were the same as those in lane 7, but the concentration of epratuzumab was too low (10 ng/mL) to induce a notable effect.
Chang, C. H., Wang, Y., Gupta, P., & Goldenberg, D. M. (2015, January). Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. In MAbs (Vol. 7, No. 1, pp. 199-211). Taylor & Francis.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1248z-S(P) | Recombinant Anti-Human CD22 Antibody scFv Fragment | ELISA, WB, IF, FuncS | scFv |
FAMAB-0046-YC-S(P) | Mouse Anti-CD22 Recombinant Antibody (clone m5/44); scFv Fragment | ELISA, Cyt | Mouse scFv |
FAMAB-0047-YC-S(P) | Human Anti-CD22 Recombinant Antibody (clone g5/44); scFv Fragment | ELISA, Cyt | Humanized scFv |
FAMAB-0048-YC-S(P) | Mouse Anti-CD22 Recombinant Antibody (clone ch5/44); scFv Fragment | ELISA | Mouse scFv |
HPAB-2052-FY-S(P) | Human Anti-CD22 Recombinant Antibody (clone B28); scFv Fragment | FC | Human scFv |
There are currently no Customer reviews or questions for TAB-0196CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.